---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-066261"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T03:15:44.371799+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sensei Bio reports Q4 2024 cash of $41.3M; Phase 1/2 solnerstotug data shows 14% ORR in PD-(L)1 resistant tumors

## Summary
- Preliminary Phase 1/2 dose expansion data: 14% ORR (3x historical PD-(L)1 rechallenge rates) and 62% DCR in PD-(L)1 resistant hot tumors; one complete response in Merkel cell carcinoma.
- Target enrollment of 60 patients achieved in dose expansion cohort; full data expected by year-end 2025.
- Net loss $30.2M for FY2024 (vs $34.1M FY2023); cash, equivalents and marketable securities $41.3M as of Dec 31, 2024, with runway into Q2 2026.
- Solnerstotug well-tolerated: no dose-limiting toxicities; majority of adverse events Grade 1-2; 7% Grade 1 cytokine release syndrome.
- Corporate updates: Q4 restructuring, appointment of Josiah Craver as Principal Financial Officer, and Dr. Ron Weitzman as part-time CMO.

## SEC filing metadata
- accession: 0001193125-25-066261
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312525066261/0001193125-25-066261-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312525066261/d927069d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-066261
- JSON: https://secwatch.observer/filing/0001193125-25-066261.json
- Plain text: https://secwatch.observer/filing/0001193125-25-066261.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.